• Dapirolizumab pegol (DZP) associated with higher response rates using the novel Treatment Response Measure for Systemic Lupus Erythematosus (TRM-SLE): A post-hoc analysis applying TRM-SLE to the DZP Phase 3 PHOENYCS GO data for the first time found greater proportions of patients receiving DZP plus standard of care (SOC) versus placebo plus SOC achieved a clinically meaningful response in at least half or all active organ domains through Week 48
• Sustained low disease activity and remission: In a separate presentation at ACR 2026, post-hoc analyses of PHOENYCS GO showed greater rates of sustained low disease activity and remission across Weeks 40, 44 and 48 with DZP plus SOC versus placebo plus SOC

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.